Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: Effects of treatment with cholinesterase inhibitors

European Journal of Neurology

Volumn 17, Issue 3, 2010, Pages 456-460

  Schultz, K ^a   Nilsson, K ^b   Nielsen, J E ^c,d   Lindquist, S G ^d   Hjermind, L E ^c,d   Andersen, B B ^d   Wallin, A ^e   Nilsson, C ^b   Petersen A ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Dementia with Lewy bodies; Transthyretin

Indexed keywords

CHOLINESTERASE INHIBITOR; PREALBUMIN;

AGED; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CHEMICAL ANALYSIS; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE MARKER; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CHOLINESTERASE INHIBITORS; COHORT STUDIES; DEPRESSION; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; PREALBUMIN; RETROSPECTIVE STUDIES;

EID: 77649165856     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02841.x     Document Type: Article

References (32)

1. Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004 9 : 705 710.
2. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008 4 : 38 48.
3. Lewczuk P, Esselmann H, Otto M, et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 2004 25 : 273 281.
4. Otto M, Lewczuk P, Wiltfang J. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods 2008 44 : 289 298.
5. Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. Dement Geriatr Cogn Disord 2004 17 : 55 64.
6. Thomas A. Clinical aspects of dementia: Alzheimer's disease. In : Jacoby R, Oppenheimer C, Dening T, Thomas A eds. Oxford Textbook of Old Age Psychiatry, 1st edn. Oxford : Oxford University Press, 2008 : 425 442.
7. Jorm AF. History of depression as a risk factor for dementia: an updated review. Aust N Z J Psychiatry 2001 35 : 776 781.
8. Hatterer JA, Herbert J, Hidaka C, Roose SP, Gorman JM. CSF transthyretin in patients with depression. Am J Psychiatry 1993 150 : 813 815.
9. Merched A, Serot JM, Visvikis S, Aguillon D, Faure G, Siest G. Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett 1998 425 : 225 228.
10. Gloeckner SF, Meyne F, Wagner F, et al. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis 2008 14 : 17 25.
11. Schwarzman AL, Gregori L, Vitek MP, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A 1994 91 : 8368 8372.
12. Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 2002 22 : 7380 7388.
13. Carro E, Torres-Aleman I. Serum insulin-like growth factor I in brain function. Keio J Med 2006 55 : 59 63.
14. Sousa JC, Grandela C, Fernandez-Ruiz J, et al. Transthyretin is involved in depression-like behaviour and exploratory activity. J Neurochem 2004 88 : 1052 1058.
15. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006 9 : 417 423.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 34 : 939 944.
17. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders : Clinical Descriptions and Diagnostic Guidelines. Geneva : World Health Organization, 1992.
18. Lofberg H, Grubb AO. Quantitation of gamma-trace in human biological fluids: indications for production in the central nervous system. Scand J Clin Lab Invest 1979 39 : 619 626.
19. Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965 2 : 235 254.
20. Buxbaum JN, Ye Z, Reixach N, et al. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A 2008 105 : 2681 2686.
21. Wati H, Kawarabayashi T, Matsubara E, et al. Transthyretin accelerates vascular Abeta deposition in a mouse model of Alzheimer's disease. Brain Pathol 2009 19 : 48 57.
22. Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006 9 : 293 348.
23. Sullivan GM, Hatterer JA, Herbert J, et al. Low levels of transthyretin in the CSF of depressed patients. Am J Psychiatry 1999 156 : 710 715.
24. Sullivan GM, Mann JJ, Oquendo MA, Lo ES, Cooper TB, Gorman JM. Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biol Psychiatry 2006 60 : 500 506.
25. Schultz K, Traskman-Bendz L, Petersen A. Transthyretin in cerebrospinal fluid from suicide attempters. J Affect Disord 2008 109 : 205 208.
26. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl 1978 271 : 5 27.
27. Biroccio A, Del Boccio P, Panella M, et al. Differential post-translational modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. Proteomics 2006 6 : 2305 2313.
28. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006 28 : 155 163.
29. Davidsson P, Westman-Brinkmalm A, Nilsson CL, et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 2002 13 : 611 615.
30. Hansson SF, Andreasson U, Wall M, et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 2009 16 : 389 397.
31. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 2003 118 : 140 146. (Pubitemid 37238996)
32. Riisoen H. Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer's disease. Acta Neurol Scand 1988 78 : 455 459.